Loading
Life sciences · Journal article
Indian Journal of Nuclear Medicine · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Recurrence of papillary thyroid cancer (PTC) beyond three decades after definitive treatment is a rare clinical event. We report a case of a 69-year-old male with PTC who had undergone near-total thyroidectomy and radioiodine remnant ablation thirty years ago, with an initial low risk of recurrence. He had an excellent response to therapy with negative Iodine-131 (I-131) whole-body scans and undetectable serum thyroglobulin (Tg) levels. In the 31st year of follow-up, chest X-ray and subsequent 18 F-FDG PET/CT, conducted to evaluate vague left-sided chest pain, revealed a solitary pulmonary nodule in the left lung lower lobe. Post video-assisted thoracoscopic surgery (VATS), histopathological analysis of the lung nodule revealed metastatic PTC. This case report emphasises that delayed recurrence of PTC at distant sites, in the absence of locoregional recurrence, must be considered as a possibility in the appropriate clinical scenario, irrespective of the initial risk of recurrence and subsequent response to therapy. It also highlights the critical role of long-term follow-up in patients with PTC.